Synonym
JTT-551; JTT551; JTT 551
IUPAC/Chemical Name
N-((5-(tert-butyl)thiazol-2-yl)methyl)-N-((4-(4-((4-(heptan-4-yl)phenoxy)methyl)phenyl)thiazol-2-yl)methyl)glycine
InChi Key
FKGBFRNVTCFMGU-UHFFFAOYSA-N
InChi Code
InChI=1S/C34H43N3O3S2/c1-6-8-25(9-7-2)26-14-16-28(17-15-26)40-22-24-10-12-27(13-11-24)29-23-41-32(36-29)20-37(21-33(38)39)19-31-35-18-30(42-31)34(3,4)5/h10-18,23,25H,6-9,19-22H2,1-5H3,(H,38,39)
SMILES Code
CCCC(CCC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)C3=CSC(=N3)CN(CC4=NC=C(S4)C(C)(C)C)CC(=O)O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
605.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fukuda S, Ohta T, Sakata S, Morinaga H, Ito M, Nakagawa Y, Tanaka M,
Matsushita M. Pharmacological profiles of a novel protein tyrosine phosphatase
1B inhibitor, JTT-551. Diabetes Obes Metab. 2010 Apr;12(4):299-306. doi:
10.1111/j.1463-1326.2009.01162.x. PMID: 20380650.
2: Ito M, Fukuda S, Sakata S, Morinaga H, Ohta T. Pharmacological effects of
JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced
obesity mice. J Diabetes Res. 2014;2014:680348. doi: 10.1155/2014/680348. Epub
2014 May 29. PMID: 24987707; PMCID: PMC4060493.
3: Liu Z, Gao H, Zhao Z, Huang M, Wang S, Zhan J. Status of research on natural
protein tyrosine phosphatase 1B inhibitors as potential antidiabetic agents:
Update. Biomed Pharmacother. 2023 Jan;157:113990. doi:
10.1016/j.biopha.2022.113990. Epub 2022 Nov 29. PMID: 36459712.
4: Singh S, Singh Grewal A, Grover R, Sharma N, Chopra B, Kumar Dhingra A, Arora
S, Redhu S, Lather V. Recent updates on development of protein-tyrosine
phosphatase 1B inhibitors for treatment of diabetes, obesity and related
disorders. Bioorg Chem. 2022 Apr;121:105626. doi: 10.1016/j.bioorg.2022.105626.
Epub 2022 Feb 24. PMID: 35255350.
